TY - JOUR
T1 - Unknown primary squamous cell carcinoma of the head and neck
T2 - retrospective analysis of 80 cases
AU - Mizuta, Masanobu
AU - Kitamura, Morimasa
AU - Tateya, Ichiro
AU - Tamaki, Hisanobu
AU - Tanaka, Shinzo
AU - Asato, Ryo
AU - Shinohara, Shogo
AU - Takebayashi, Shinji
AU - Maetani, Toshiki
AU - Kitani, Yoshiharu
AU - Kumabe, Yohei
AU - Kojima, Tsuyoshi
AU - Ushiro, Koji
AU - Ichimaru, Kazuyuki
AU - Honda, Keigo
AU - Yamada, Koichiro
AU - Omori, Koichi
N1 - Publisher Copyright:
© 2018 Acta Oto-Laryngologica AB (Ltd).
PY - 2018/6/3
Y1 - 2018/6/3
N2 - Objectives: The management of patients with cervical metastasis in head and neck cancer of unknown primary (HNCUP) remains controversial. This current multicenter retrospective study investigated the treatment outcomes of patients with HNCUP. Methods: The study included patients who were treated curatively at 12 institutions in Japan from January 2006 to December 2015. Results: Eighty patients with HNCUP were included. The median follow-up period was 34 months. The three-year overall survival (OS), disease-specific survival (DSS), regional relapse-free survival (RRFS), local progression-free survival (LPFS), and distant metastasis-free survival (DMFS) rates were 72.5%, 80.3%, 74.0%, 89.7%, and 86.9%, respectively. Nodal status was a significant factor for OS, DSS, RRFS, and DMFS; and extracapsular extension (ECE) was significant for OS and DSS. There was a distinct difference between the survival rates of patients with N1–2a and N2b–3 disease. RT was a significant positive factor for LPFS (3-year LPFS, RT 93.0% vs. no RT 83.0%, p =.043). Conclusions: For N2a as well as N1 disease without ECE, a single treatment modality, including ND or RT alone is acceptable. When ND alone is performed, thorough monitoring should be continued during follow-up to identify the emergence of the primary lesion.
AB - Objectives: The management of patients with cervical metastasis in head and neck cancer of unknown primary (HNCUP) remains controversial. This current multicenter retrospective study investigated the treatment outcomes of patients with HNCUP. Methods: The study included patients who were treated curatively at 12 institutions in Japan from January 2006 to December 2015. Results: Eighty patients with HNCUP were included. The median follow-up period was 34 months. The three-year overall survival (OS), disease-specific survival (DSS), regional relapse-free survival (RRFS), local progression-free survival (LPFS), and distant metastasis-free survival (DMFS) rates were 72.5%, 80.3%, 74.0%, 89.7%, and 86.9%, respectively. Nodal status was a significant factor for OS, DSS, RRFS, and DMFS; and extracapsular extension (ECE) was significant for OS and DSS. There was a distinct difference between the survival rates of patients with N1–2a and N2b–3 disease. RT was a significant positive factor for LPFS (3-year LPFS, RT 93.0% vs. no RT 83.0%, p =.043). Conclusions: For N2a as well as N1 disease without ECE, a single treatment modality, including ND or RT alone is acceptable. When ND alone is performed, thorough monitoring should be continued during follow-up to identify the emergence of the primary lesion.
KW - Unknown primary
KW - cervical lymph node
KW - neck dissection
KW - radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85041015969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041015969&partnerID=8YFLogxK
U2 - 10.1080/00016489.2017.1422141
DO - 10.1080/00016489.2017.1422141
M3 - Article
C2 - 29310489
AN - SCOPUS:85041015969
SN - 0001-6489
VL - 138
SP - 590
EP - 596
JO - Acta Oto-Laryngologica
JF - Acta Oto-Laryngologica
IS - 6
ER -